AKT1 and hepatocellular carcinoma: The potential compensation mechanism presented by the PI3K/AKT pathway can cause sorafenib resistance in HCC patients.162,163 Accordingly, by inhibiting the multiple pathways involved in HCC, a more effective survival outcome is likely to be achieved with a combination of targeted therapies.